BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 28557601)

  • 1. FDA Oversight of Laboratory-Developed Tests: Where Are We Now?
    Gatter K
    Arch Pathol Lab Med; 2017 Jun; 141(6):746-748. PubMed ID: 28557601
    [No Abstract]   [Full Text] [Related]  

  • 2. US Food and Drug Administration regulatory oversight of laboratory-developed tests: Commentary on the draft guidance.
    Sidawy MK
    Cancer Cytopathol; 2015 Oct; 123(10):573-5. PubMed ID: 26042383
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA and CLIA oversight of advanced diagnostics and biomarker tests.
    Terry SF
    Genet Test Mol Biomarkers; 2010 Jun; 14(3):285-7. PubMed ID: 20578940
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA oversight of laboratory-developed tests: is it necessary, and how would it impact clinical laboratories?
    Scott MG; Ashwood ER; Annesley TM; Leonard DG; Burgess MC
    Clin Chem; 2013 Jul; 59(7):1017-22. PubMed ID: 23536512
    [No Abstract]   [Full Text] [Related]  

  • 5. Ensuring quality in genomic medicine: amid the rise in complex laboratory-developed tests, regulatory officials are seeking the right balance on quality assurance.
    Nelson B
    Cancer Cytopathol; 2014 Dec; 122(12):855-6. PubMed ID: 25510938
    [No Abstract]   [Full Text] [Related]  

  • 6. How will the FDA impact the laboratory developed test?
    Davis J; Wentz J
    Clin Lab Sci; 2007; 20(3):130-1. PubMed ID: 17691668
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA oversight of laboratory-developed tests will facilitate adoption of pharmacogenetic testing into routine clinical care.
    Hillebrenner E; Litwack E; Bradley P; Donigan K; Lowe T; Serrano K; Kelm K; Mansfield E; Gutierrez A
    J Clin Pharmacol; 2015 Jul; 55(7):728-30. PubMed ID: 26053648
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA announces plans to regulate LDTs.
    Cancer Discov; 2014 Nov; 4(11):1250. PubMed ID: 25367935
    [No Abstract]   [Full Text] [Related]  

  • 9. Code of Federal Regulations (CFRs): where it all begins.
    Kreuger J; Stengl A; Skalitzky D; Wehmeyer P
    Qual Assur; 1994 Mar; 3(1):82-7. PubMed ID: 7804622
    [No Abstract]   [Full Text] [Related]  

  • 10. Modification of In Vitro Diagnostic Devices: Leveling the Playing Field.
    Rychert J; Delgado JC; Genzen JR
    Clin Chem; 2020 Jun; 66(6):760-762. PubMed ID: 32278318
    [No Abstract]   [Full Text] [Related]  

  • 11. FDA and clinical labs: beginning a dialogue.
    Javitt G
    MLO Med Lab Obs; 2007 May; 39(5):52, 50. PubMed ID: 18396740
    [No Abstract]   [Full Text] [Related]  

  • 12. Looming regulations and FDA oversight mean an uncertain reimbursement climate in 2016.
    Wolf R
    MLO Med Lab Obs; 2016 May; 48(5):26-7. PubMed ID: 27323455
    [No Abstract]   [Full Text] [Related]  

  • 13. Laboratory-developed tests are not the practice of medicine.
    Allen JS
    MLO Med Lab Obs; 2015 Sep; 47(9):46. PubMed ID: 26495599
    [No Abstract]   [Full Text] [Related]  

  • 14. "Research use only" reagents: is there an imperative for increased FDA oversight?
    O'Leary TJ
    Clin Chem; 2011 Dec; 57(12):1681-3. PubMed ID: 21998341
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA Announces Increased Oversight of Some Diagnostic Laboratory Tests.
    Harris E
    JAMA; 2024 Jun; 331(24):2071. PubMed ID: 38819803
    [No Abstract]   [Full Text] [Related]  

  • 16. Facing the Inevitable: Being Prepared for Regulatory Requirements for Laboratory Developed Tests.
    D'Angelo R; Weiss R; Wolfe D; Chinnam R; Murat A; Gluesing J; Somers T
    Am J Clin Pathol; 2018 Apr; 149(6):484-498. PubMed ID: 29659675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compounding oversight a work in progress for states, FDA.
    Traynor K
    Am J Health Syst Pharm; 2016 Apr; 73(7):424-5. PubMed ID: 27001978
    [No Abstract]   [Full Text] [Related]  

  • 18. FDA regulation of laboratory-developed diagnostic tests: protect the public, advance the science.
    Sharfstein J
    JAMA; 2015 Feb; 313(7):667-8. PubMed ID: 25560381
    [No Abstract]   [Full Text] [Related]  

  • 19. A comparison of the U.S. EPA FIFRA GLP standards with the U.S. FDA GLP standards for nonclinical laboratory studies.
    Keatley KL
    Qual Assur; 1999; 7(3):147-54. PubMed ID: 11033740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA set to tighten guidelines on industry dissemination of information on unapproved uses of medical products.
    Lang L
    Gastroenterology; 2008 Apr; 134(4):905. PubMed ID: 18395067
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.